Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co.

Baillie Gifford & Co. lowered its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 2.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,278,084 shares of the company's stock after selling 293,116 shares during the period. Baillie Gifford & Co. owned approximately 4.62% of Sana Biotechnology worth $42,757,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SANA. China Universal Asset Management Co. Ltd. boosted its holdings in Sana Biotechnology by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 42,787 shares of the company's stock valued at $178,000 after purchasing an additional 16,764 shares during the last quarter. Bristlecone Advisors LLC acquired a new position in shares of Sana Biotechnology in the 3rd quarter valued at approximately $208,000. Blue Trust Inc. boosted its stake in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock valued at $55,000 after buying an additional 12,154 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Sana Biotechnology during the second quarter worth approximately $73,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Sana Biotechnology by 8.0% in the second quarter. The Manufacturers Life Insurance Company now owns 312,031 shares of the company's stock worth $1,704,000 after buying an additional 23,157 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the company's stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares in the company, valued at $11,620,333.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 31.10% of the company's stock.

Wall Street Analyst Weigh In

SANA has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of Sana Biotechnology in a research note on Monday. Citigroup lifted their price target on Sana Biotechnology from $8.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Finally, JMP Securities lowered Sana Biotechnology from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 5th.

Sana Biotechnology Stock Down 6.3 %

SANA stock traded down $0.18 during trading on Wednesday, hitting $2.66. 1,965,112 shares of the company's stock traded hands, compared to its average volume of 2,149,094. The stock has a fifty day moving average price of $4.09 and a two-hundred day moving average price of $5.69. Sana Biotechnology, Inc. has a 52 week low of $2.62 and a 52 week high of $12.00.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Research analysts predict that Sana Biotechnology, Inc. will post -1.14 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.